See All Slides - tctmd.com

Slides

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

Insights From the PCI Arms in EXCEL and NOBLE: Can the Outcomes Be Further Improved?

Presenter: Antonio Colombo, David E. Kandzari, Marie-Claude Morice

October 31, 2017

Presentation TCT 2017

Acute Cardiogenic Shock: The Case for First-line Use of Impella

Presenter: Vladimir Dzavik, Navin K. Kapur, Mark B. Anderson

October 31, 2017

Presentation TCT 2017

Established TMVR 4: Intrepid - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Vinayak Bapat

October 31, 2017

Presentation TCT 2017

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Presenter: Azeem Latib, Dean J. Kereiakes

October 31, 2017

Presentation TCT 2017

In Which Direction is Cell Based Heart Failure Therapy Headed?

Presenter: Francisco Fdez-Aviles, Emerson C. Perin

October 31, 2017

Presentation TCT 2017

How to Align Incentives in the Cath Lab

Presenter: Peter L Duffy, Hadley Wilson, Herbert D. Aronow

October 31, 2017

Presentation TCT 2017

FDA Perspectives on TAVR Label Expansion Using Real-World Evidence, Valve Degeneration, and Embolic Protection Devices

Presenter: Martin B. Leon, Changfu Wu, John C Laschinger

October 31, 2017

Presentation TCT 2017

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Presenter: Michael J. Reardon

October 31, 2017

Presentation TCT 2017

Master Perspectives: Compared to Medical Therapy, Does CTO PCI Improve Prognosis, or Are the Main Benefits Symptomatic Improvement?

Presenter: Barry D. Rutherford, Robert W. Yeh

October 31, 2017

Advertisement

Slides

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Insights From the PCI Arms in EXCEL and NOBLE: Can the Outcomes Be Further Improved?

Acute Cardiogenic Shock: The Case for First-line Use of Impella

Established TMVR 4: Intrepid - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

In Which Direction is Cell Based Heart Failure Therapy Headed?

How to Align Incentives in the Cath Lab

FDA Perspectives on TAVR Label Expansion Using Real-World Evidence, Valve Degeneration, and Embolic Protection Devices

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Master Perspectives: Compared to Medical Therapy, Does CTO PCI Improve Prognosis, or Are the Main Benefits Symptomatic Improvement?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content